Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Todd W. Ridky, MD, PhD

Todd W. Ridky, MD, PhD Physician

Assistant Professor of Dermatology

Dr. Ridky is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Dermatology

Programs & Centers:

Board Certification:

  • Dermatology, 2003

Description of Clinical Expertise

General Dermatology

Practice Locations and Appointments

  • Penn Dermatology

    Perelman Center for Advanced Medicine South Pavilion, 1st Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Case Western Reserve University School of Medicine
Residency: MetroHealth Medical Center
Residency: Stanford University Medical Center
Fellowship: Stanford University Medical Center

Memberships

American Academy of Dermatology, National American Association for Cancer Research, National Society for Investigative Dermatology, International Society for Investigative Dermatology, International Society for Investigative Dermatology, National

Hospital Affiliation

Dr. Ridky is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Epithelial biology
Gene regulatory control of epidermal homeostasis
Epithelial oncogenesis
Tissue models of human malignancy

Description of Research:
The Ridky Lab uses genetically-defined, engineered epithelial tissues as an experimental platform to study pathways driving human cancer initiation, stromal invasion, tumor-stroma interaction, metastasis, and maintenance of cancer stem cells. Tissue models of invasive malignancy are used to identify and validate new targets for potential therapeutics. To maximize the physiologic and medical relevance of our efforts, we develop experimental human tissue systems based on normal primary human cells established within an architecturally faithful native 3-D environment incorporating intact mesenchymal stroma and living stromal cells. Progression to cancer is driven by genetic changes initially identified in spontaneous tumors in humans and specifically engineered into the model tissues. Many experiments are conducted entirely in this organotypic environment, while in vivo studies utilize immunodeficient mice as hosts for the engineered tissues. These new models allow up to 10 alleles or more to be altered simultaneously in 1-2 days, permitting genetic experiments with an unprecedented degree of rapidity and complexity exceeding that previously possible in traditional genetic experimental organisms, such as transgenic mice. These new genetic models, which we refer to as "Multifunctional Human Tissue Genetics", have allowed us to directly convert multiple normal human tissues into invasive cancer via targeted, specific alterations in defined, medically-relevant genetic networks. Bioinformatics-intensive systems biology approaches are used to identify centrally-acting elements that are likely important for promoting cancer progression. To determine functional roles for specific tumor cell or stromal cell-intrinsic factors, we employ various genetic and protein level interventions, including multiplexed expression of tumor-associated mutant oncogenic drivers, tumor suppressors, and conditionally active proteins. Disruption of primary oncogenic signaling and non-oncogene addicted (NOA) pathways is achieved via RNA interference (RNAi), as well as chemical small molecule inhibitors and protein based biologic agents as a foundation for development of targeted molecular therapeutics.

Lab Personnel:
Andrew McNeal - Research Specialist
Emily Schapira - UPenn (2013)
Kevin Liu - UPenn (2013)
Vihang Nakhate - UPenn (2014)
Seung Ja Oh - Postdoctoral fellow

Lab Web Page:
http://www.med.upenn.edu/ridkylab/

Selected Publications:

Natale Christopher A, Duperret Elizabeth K, Zhang Junqian, Sadeghi Rochelle, Dahal Ankit, O'Brien Kevin Tyler, Cookson Rosa, Winkler Jeffrey D, Ridky Todd W: Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors. eLife 5 : 2016.

Cárdenas César, Müller Marioly, McNeal Andrew, Lovy Alenka, Jana Fabian, Bustos Galdo, Urra Felix, Smith Natalia, Molgó Jordi, Diehl J Alan, Ridky Todd W, Foskett J Kevin: Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria. Cell reports 14 (10): 2313-24,2016.

Capell Brian C, Drake Adam M, Zhu Jiajun, Shah Parisha P, Dou Zhixun, Dorsey Jean, Simola Daniel F, Donahue Greg, Sammons Morgan, Rai Taranjit Singh, Natale Christopher, Ridky Todd W, Adams Peter D, Berger Shelley L: MLL1 is essential for the senescence-associated secretory phenotype. Genes & development 30 (3): 321-36,2016.

Zhorov, Irina: Penn researchers use hormones to change skin tone NPR Radio (WHYY) Newsworks "The pulse" : 2016.

Duperret Elizabeth K, Dahal Ankit, Ridky Todd W: Focal adhesion-independent integrin av regulation of FAK and c-myc is necessary for 3D skin formation and tumor invasion. Journal of cell science 128 (21): 3997-4013,2015.

Jessica McDonald: When Moles Go Bad: Penn Scientists Identify Commonly Lost Protein That Protects Against Melanoma NPR, newsworks.org, WHYY radio : 2015.

Todd Ridky interviewed by Dan Loney: Moles and Melanoma Knowledge@Wharton SIRIUS XM National Radio Broadcast Host Dan Loney Interview with Todd Ridky regarding Moles, Melanoma, and P15 : 2015.

McNeal Andrew S, Liu Kevin, Nakhate Vihang, Natale Christopher A, Duperret Elizabeth K, Capell Brian C, Dentchev Tzvete, Berger Shelley L, Herlyn Meenhard, Seykora John T, Ridky Todd W: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discovery 5 (10): 1072-85,2015.

Monteleon Christine L, McNeal Andrew, Duperret Elizabeth K, Oh Seung J, Schapira Emily, Ridky Todd W: IQGAP1 and IQGAP3 Serve Individually Essential Roles in Normal Epidermal Homeostasis and Tumor Progression. The Journal of investigative dermatology 135 (9): 2258-65,2015.

Ridky Todd W, Cotsarelis George: Vismodegib resistance in basal cell carcinoma: not a smooth fit. Cancer cell 27 (3): 315-6,2015.

View all publications

Academic Contact Info

Department of Dermatology
University of Pennsylvania
1010 Biomedical Research Building
421 Curie Blvd

Philadelphia, PA 19104
Phone: (215) 573-5709
Patient appointments: 800-789-PENN (7366)

Related Links